Cargando…

A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine

OBJECTIVE: This study aimed to explore whether treatment with the glucagon-like peptide-1 (GLP-1) analog liraglutide reduces intimal hyperplasia after coronary stent implantation via regulation of glycemic variability, the NLRP3 inflammasome, and IL-10 in diabetic swine. METHODS: Fifteen pigs were d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Jinggang, Li, Qinxue, Liu, Yayun, Ren, Quanxin, Gao, Jinhuan, Tian, Yi, Li, Jubo, Zhang, Baojie, Sun, Haichen, Liu, Shuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113385/ https://www.ncbi.nlm.nih.gov/pubmed/32273846 http://dx.doi.org/10.3389/fphar.2020.00372

Ejemplares similares

The effects of glycaemic variability on intimal hyperplasia and plaque stability after stenting via autophagy-mediated G3BP1/NLRP3 inflammasome
por: Xia, Jinggang, et al.
Publicado: (2020)

Glycemic variability is associated with vascular calcification by the markers of endoplasmic reticulum stress-related apoptosis, Wnt1, galectin-3 and BMP-2
por: Zhang, Li, et al.
Publicado: (2019)

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
por: van Can, J, et al.
Publicado: (2014)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study
por: Ishii, Hitoshi, et al.
Publicado: (2017)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Vitamin D Supplementation Reduces Intimal Hyperplasia and Restenosis following Coronary Intervention in Atherosclerotic Swine
por: Gupta, Gaurav K., et al.
Publicado: (2016)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome
por: Ammar, Reham A., et al.
Publicado: (2022)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

The NLRP6 inflammasome
por: Zheng, Danping, et al.
Publicado: (2020)

Photochemical Tissue Passivation Reduces Vein Graft Intimal Hyperplasia in a Swine Model of Arteriovenous Bypass Grafting
por: Goldstone, Robert N., et al.
Publicado: (2016)

IL-22 alleviates the fibrosis of hepatic stellate cells via the inactivation of NLRP3 inflammasome signaling
por: Xing, Zhuyun, et al.
Publicado: (2021)

Acute Glycemic Control in Prediabetes Individuals Favorably Alters Serum NLRP3 Inflammasome and Related Interleukins
por: Alfadul, Hend, et al.
Publicado: (2023)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways
por: Rakipovski, Günaj, et al.
Publicado: (2018)

GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy
por: Shiraki, Aya, et al.
Publicado: (2019)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Amentoflavone Affects Epileptogenesis and Exerts Neuroprotective Effects by Inhibiting NLRP3 Inflammasome
por: Rong, Shikuo, et al.
Publicado: (2019)

Inhibiting the NLRP3 Inflammasome
por: El-Sharkawy, Lina Y., et al.
Publicado: (2020)

GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway
por: Chen, Xiangheng, et al.
Publicado: (2021)

Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
por: Dharmalingam, Mala, et al.
Publicado: (2011)

The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction
por: Diz-Chaves, Y., et al.
Publicado: (2018)

Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
por: Ismail, Ruba, et al.
Publicado: (2019)

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
por: Inoue, Kana, et al.
Publicado: (2014)

Tofacitinib restores the balance of γδTreg/γδT17 cells in rheumatoid arthritis by inhibiting the NLRP3 inflammasome
por: Yang, Xinyu, et al.
Publicado: (2021)

Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome
por: Zhang, Tan, et al.
Publicado: (2021)

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
por: Saresella, Marina, et al.
Publicado: (2016)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
por: Vandemark, Collin, et al.
Publicado: (2023)

Analysis of arterial intimal hyperplasia: review and hypothesis
por: Subbotin, Vladimir M
Publicado: (2007)

Neo-intimal hyperplasia, diabetes and endovascular injury
por: Kruger, Deirdré
Publicado: (2012)

Synergy of Rapamycin and Cyanoacrylate in Reducing Intimal Hyperplasia
por: Koike, Marcia Kiyomi
Publicado: (2019)

The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney
por: Kim, Yang Gyun, et al.
Publicado: (2019)

Salvianolic Acid A Ameliorates Early-Stage Atherosclerosis Development by Inhibiting NLRP3 Inflammasome Activation in Zucker Diabetic Fatty Rats
por: Ma, Quanxin, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
por: Krasner, Nadia M., et al.
Publicado: (2014)

The role of the NLRP3 inflammasome in gout
por: Kingsbury, Sarah R, et al.
Publicado: (2011)

The Role of the NLRP3 Inflammasome in Fibrosis
por: Artlett, Carol M
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6cdngkel9bs4k1gd6bj02ekvmm